{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:22Z","timestamp":1791920902740,"version":"4.3.4"},"reference-count":125,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite widely available antiretroviral therapy, lymphoma remains the leading cause of death for human immunodeficiency virus (HIV)\u2013infected persons in economically developed countries. Even a few months of drug interruptions can lead to drops in the CD4 cell count, HIV viremia, and an increased risk of lymphoma. Currently, good HIV control facilitates intensive therapies appropriate to the lymphoma, including autologous and even allogeneic hematopoietic stem cell transplantation. Nonetheless, HIV-related lymphomas have unique aspects, including pathogenetic differences driven by the presence of HIV and often coinfection with oncogenic viruses. Future therapies might exploit these differences. Lymphoma subtypes also differ in the HIV-infected population, and the disease has a higher propensity for advanced-stage, aggressive presentation and extranodal disease. Other unique aspects include the need to avoid potential interactions between antiretroviral therapy and chemotherapeutic agents and the need for HIV-specific supportive care such as infection prophylaxis. Overall, the care of these patients has progressed sufficiently that recent guidelines from the American Society of Clinical Oncology advocate the inclusion of HIV-infected patients alongside HIV-negative patients in cancer clinical trials when appropriate. This article examines HIV lymphoma and includes Burkitt lymphoma in the general population.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000448","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T21:02:18Z","timestamp":1591909338000},"page":"260-268","source":"Crossref","is-referenced-by-count":27,"title":["HIV Lymphoma and Burkitts Lymphoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Ariela","family":"Noy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/L16-0091","article-title":"Update of survival for persons with HIV infection in Denmark","volume":"165","year":"2016","journal-title":"Ann Intern Med"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.qco.0000200295.30285.13","article-title":"AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy","volume":"19","year":"2006","journal-title":"Curr Opin Infect Dis"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/QAI.0b013e31817aebfe","article-title":"Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study","volume":"48","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","article-title":"Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992\u20132003","volume":"148","year":"2008","journal-title":"Ann Intern Med"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","year":"2004","journal-title":"AIDS"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1002\/cncr.25530","article-title":"Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"bib8-20230924","first-page":"1548","article-title":"Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980\u20132007","volume":"306","year":"2011","journal-title":"JAMA"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","article-title":"Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study","volume":"28","year":"2014","journal-title":"AIDS"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7326\/M14-2768","article-title":"Cumulative incidence of cancer among persons with HIV in North America: a cohort study","volume":"163","year":"2015","journal-title":"Ann Intern Med"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1200\/JCO.2005.11.973","article-title":"AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome\u2013related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","article-title":"Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus\u2013associated Burkitt lymphoma","volume":"98","year":"2003","journal-title":"Cancer"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome\u2013related Burkitt lymphoma\/leukemia","volume":"94","year":"2002","journal-title":"Cancer"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1182\/blood-2006-02-003178","article-title":"K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis","volume":"109","year":"2007","journal-title":"Blood"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/cid\/civ627","article-title":"High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR cohort","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","year":"1997","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0046-8177(97)90137-4","article-title":"AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors","volume":"28","year":"1997","journal-title":"Hum Pathol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/neuonc\/now155","article-title":"Long-term survival in AIDS-related primary central nervous system lymphoma","volume":"19","year":"2017","journal-title":"Neuro Oncol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1212\/WNL.0000000000004265","article-title":"Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy","volume":"89","year":"2017","journal-title":"Neurology"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood-2008-09-180315","article-title":"HIV-associated lymphomas and gamma-herpesviruses","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3851\/IMP1462","article-title":"Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study","volume":"14","year":"2009","journal-title":"Antivir Ther"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0b013e3282ed6338","article-title":"Risk of cancers during interrupted antiretroviral therapy in the SMART study","volume":"21","year":"2007","journal-title":"AIDS"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2009.25.1322","article-title":"Circulating serum free light chains as predictive markers of AIDS-related lymphoma","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1055-9965.EPI-11-0037","article-title":"B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma","volume":"20","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/QAD.0b013e328332d5b1","article-title":"Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study","volume":"24","year":"2010","journal-title":"AIDS"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/ijc.29494","article-title":"A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting","volume":"137","year":"2015","journal-title":"Int J Cancer"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"15678","DOI":"10.1002\/jcp.28219","article-title":"HIV-1 Tat protein induces aberrant activation of AICDA in human B-lymphocytes from peripheral blood","volume":"234","year":"2019","journal-title":"J Cell Physiol"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/leu.2017.106","article-title":"HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.redox.2017.11.024","article-title":"HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production","volume":"15","year":"2018","journal-title":"Redox Biol"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00002030-200103090-00001","article-title":"The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme beta-polymerase","volume":"15","year":"2001","journal-title":"AIDS"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.179.3.961","article-title":"The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 Tat protein","volume":"179","year":"1994","journal-title":"J Exp Med"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1023892223074","article-title":"HIV-1 Tat protein and endothelium: from protein\/cell interaction to AIDS-associated pathologies","volume":"5","year":"2002","journal-title":"Angiogenesis"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The whole-genome landscape of Burkitt lymphoma subtypes","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2010.02.146","article-title":"Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes","volume":"396","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semcancer.2009.07.004","article-title":"Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology","volume":"19","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07943.x","article-title":"Genome wide DNA-profiling of HIV-related B-cell lymphomas","volume":"148","year":"2010","journal-title":"Br J Haematol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","year":"1996","journal-title":"Nature"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V93.6.1838.406k39_1838_1842","article-title":"Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1\u2013infected individuals","volume":"93","year":"1999","journal-title":"Blood"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib48-20230924","first-page":"2017","article-title":"AIDS-related lymphomas: clinical manifestations, diagnosis, and staging of systemic lymphoma","volume":"31","year":"2017","journal-title":"UptoDate"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib50-20230924","first-page":"3755","article-title":"Frequent mutation of the 5\u2032 noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome\u2013related non-Hodgkin's lymphomas","volume":"89","year":"1997","journal-title":"Blood"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/QAD.0b013e328010ac5b","article-title":"Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status","volume":"20","year":"2006","journal-title":"AIDS"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199706053362304","article-title":"Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-9343(93)90259-R","article-title":"Human immunodeficiency virus\u2013related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group","volume":"95","year":"1993","journal-title":"Am J Med"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428199409049677","article-title":"Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen","volume":"14","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2004.08.195","article-title":"Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","article-title":"Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","article-title":"Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era","volume":"31","year":"2017","journal-title":"AIDS"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.V128.22.469.469","article-title":"Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-Cell lymphoma: CALGB\/Alliance 50303","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-642-56352-2_18","article-title":"Infusional CDE with rituximab for the treatment of human immunodeficiency virus\u2013associated non-Hodgkin's lymphoma: preliminary results of a phase I\/II study","volume":"159","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","year":"2005","journal-title":"Blood"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","article-title":"Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma","volume":"118","year":"2012","journal-title":"Cancer"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2141.2012.09046.x","article-title":"Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP","volume":"157","year":"2012","journal-title":"Br J Haematol"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cncr.21759","article-title":"Acquired immunodeficiency syndrome\u2013related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival\u2014results of the German Multicenter Trial","volume":"106","year":"2006","journal-title":"Cancer"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus\u2013associated diffuse large B-cell lymphoma: results of a phase II trial","volume":"140","year":"2008","journal-title":"Br J Haematol"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","article-title":"A new prognostic score for AIDS-related lymphomas in the rituximab-era","volume":"99","year":"2014","journal-title":"Haematologica"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1097\/00002030-200108170-00005","article-title":"Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy","volume":"15","year":"2001","journal-title":"AIDS"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10428194.2017.1334121","article-title":"Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)\u2013related diffuse large B-cell lymphoma","volume":"59","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","year":"2000","journal-title":"Nature"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","year":"2004","journal-title":"Blood"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/modpathol.3800493","article-title":"AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles","volume":"19","year":"2006","journal-title":"Mod Pathol"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/blood.V118.21.1629.1629","article-title":"Rituxiamb did not improve clinical outcomes in AIDS-related Burkitt lymphoma","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib77-20230924","first-page":"735392","article-title":"HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M\/IVAC with or without rituximab in the HAART era","volume":"2012","year":"2012","journal-title":"Adv Hematol"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus\u2013infected and noninfected patients","volume":"113","year":"2008","journal-title":"Cancer"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hon.2437_122","article-title":"Risk-adapted therapy in adults with Burkitt lymphoma: updated results of a multicenter prospective phase II study of DA-EPOCH-R","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdh399","article-title":"CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients","volume":"15","year":"2004","journal-title":"Ann Oncol"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3109\/10428194.2015.1113281","article-title":"Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium","volume":"57","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","year":"2015","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"bib83-20230924","first-page":"1588","article-title":"A randomized trial of EPOCH-based chemotherapy with vorinostat for highly aggressive HIV-associated lymphomas: updated results evaluating impact of diagnosis-to-treatment interval (DTI) and pre-protocol systemic therapy on outcomes","volume":"134","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"bib84-20230924","first-page":"1595","article-title":"A multicenter, open-label feasibility study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma: AIDS Malignancy Consortium 105","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/JCO.1999.17.2.554","article-title":"Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma","volume":"17","year":"1999","journal-title":"J Clin Oncol"},{"key":"bib86-20230924","first-page":"199","article-title":"Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)\u2013related primary central nervous system lymphoma (PCNSL)","volume":"9","year":"1998","journal-title":"Crit Rev Oncog"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3816\/CLM.2006.n.017","article-title":"Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019","volume":"6","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2002-10-3090","article-title":"Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/blood-2007-05-092288","article-title":"The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2007.06879.x","article-title":"KSHV\/HHV8-associated lymphomas","volume":"140","year":"2008","journal-title":"Br J Haematol"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/jcp.2007.047969","article-title":"Kaposi sarcoma-associated herpesvirus\/human herpesvirus 8 and lymphoproliferative disorders","volume":"60","year":"2007","journal-title":"J Clin Pathol"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI44417","article-title":"Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice","volume":"121","year":"2011","journal-title":"J Clin Invest"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.24251","article-title":"Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution","volume":"91","year":"2016","journal-title":"Am J Hematol"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-08-2525","article-title":"Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","year":"2006","journal-title":"Blood"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2004.04934.x","article-title":"Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus\u2013associated Hodgkin's disease","volume":"125","year":"2004","journal-title":"Br J Haematol"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10428194.2016.1201573","article-title":"Feasibility of interim positron emission tomography (PET)\u2013adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial","volume":"58","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","article-title":"Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"bib101-20230924","first-page":"130","article-title":"Safety and efficacy of brentuximab vedotin in combination with AVD in stage II\u2013IV HIV-associated classical Hodgkin lymphoma: results of the phase 2 study, AMC 085","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8\u2013negative\/idiopathic multicentric Castleman disease","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2016-10-747477","article-title":"Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2004-04-1532","article-title":"Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib105-20230924","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(00)02041-9","article-title":"High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1\u2013associated lymphoma","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1200\/JCO.2003.06.039","article-title":"High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2009-02-202762","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2008.18.2683","article-title":"Autologous stem-cell transplantation in patients with HIV-related lymphoma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable survival between HIV+ and HIV\u2212 non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bbmt.2010.03.019","article-title":"HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL)","volume":"16","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803\/AMC 071 trial","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib112-20230924","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood.V99.2.698","article-title":"Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome","volume":"99","year":"2002","journal-title":"Blood"},{"key":"bib113-20230924","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbmt.2009.03.023","article-title":"Allogeneic hematopoietic cell transplantation in human immunodeficiency virus\u2013positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research","volume":"15","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib114-20230924","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2017.35.15_suppl.7006","article-title":"Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)\/AIDS Malignancy Consortium (AMC-080) trial","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib115-20230924","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"bib116-20230924","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","year":"2019","journal-title":"Cancer"},{"key":"bib119-20230924","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"bib120-20230924","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/QCO.0b013e3283420f76","article-title":"Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections","volume":"24","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"bib121-20230924","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00002030-200203080-00003","article-title":"Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma","volume":"16","year":"2002","journal-title":"AIDS"},{"key":"bib122-20230924","first-page":"1","article-title":"Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"bib123-20230924","first-page":"36ra43","article-title":"RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma","volume":"2","year":"2010","journal-title":"Sci Transl Med"},{"key":"bib124-20230924","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research HIV Working Group","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib125-20230924","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pbc.20254","article-title":"The 2000 Burkitt lymphoma trial in Malawi","volume":"44","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"bib126-20230924","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/mpo.10322","article-title":"Malawi pilot study of Burkitt lymphoma treatment","volume":"41","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"bib127-20230924","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/1097-0215(20010601)92:5<687::AID-IJC1246>3.0.CO;2-Z","article-title":"Adult Burkitt's lymphoma in patients with and without human immunodeficiency virus infection in Kenya","volume":"92","year":"2001","journal-title":"Int J Cancer"},{"key":"bib128-20230924","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1200\/JCO.2008.18.7641","article-title":"Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa","volume":"27","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T12:58:55Z","timestamp":1723035535000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000448","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}